1 – 17 of 17
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Efficient Wideband mmW Transceiver Front End for 5G Base Stations in 22-nm FD-SOI CMOS
(
- Contribution to journal › Article
- 2018
-
Mark
Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)
(
- Contribution to journal › Article
-
Mark
Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors—A Scandinavian Sarcoma Group study (SSG XX)
(
- Contribution to journal › Article
- 2015
-
Mark
Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase 2 study by The Nordic Lymphoma Group.
(
- Contribution to journal › Article
- 2014
-
Mark
Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry
(
- Contribution to journal › Article
-
Mark
The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab
(
- Contribution to journal › Article
- 2012
-
Mark
Upfront Autologuos Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01.
(
- Contribution to journal › Article
- 2011
-
Mark
Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study.
(
- Contribution to journal › Article
-
Mark
Long term risk of infections in Hodgkin lymphoma long-term survivors.
(
- Contribution to journal › Letter
-
Mark
T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
(
- Contribution to journal › Article
-
Mark
A 9-band WCDMA/EDGE transceiver supporting HSPA evolution
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
- 2010
-
Mark
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma
(
- Contribution to journal › Article
-
Mark
Favorable Outcome In ALK Negative Anaplastic Large Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT) a Prospective Study by the Nordic Lymphoma Group (NLG T 01)
(
- Contribution to journal › Published meeting abstract
-
Mark
Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy Associated T Cell Lymphoma a Prospective Study by the Nordic Lymphoma Group (NLG T 01)
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Sensitivity degradation in a tri-band GSM BiCMOS direct-conversion receiver caused by transient substrate heating
(
- Contribution to journal › Article
-
Mark
Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
(
- Contribution to journal › Article
-
Mark
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group
(
- Contribution to journal › Article